Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Abstract

Natalizumab exerts impressive therapeutic effects in patients with multiple sclerosis (MS). The proposed main mode of action is reducing transmigration of leukocytes into the CNS, but other immunological effects may also be operative. Cytokines and chemokines are involved in the regulation of inflammatory responses and may reflect the disease process in MS. The objective of this study was to evaluate the effects of natalizumab treatment on cytokine and chemokine profiles systemically and intrathecally in multiple sclerosis. We used luminex to analyse a panel of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF) and chemokines (CXCL9, CXCL10, CXCL11, CCL17, CCL22) in blood and cerebrospinal fluid (CSF) from 31 patients with relapsing MS before and after one year of natalizumab treatment. There was a marked decline in CSF levels of cytokines and chemokines, thus including pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) as well as chemokines associated with both Th1 (CXCL9, CXCL10, CXCL11) and Th2 (CCL22). Circulating plasma levels of some cytokines (GM-CSF, TNF-α, IL-6 and IL-10) also decreased after one year of treatment. This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level. This finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizumab treatment.

Keywords

cerebrospinal fluid chemokines cytokines luminex multiple sclerosis natalizumab peripheral blood

Get full access to this article

View all access options for this article.

References

Rice GP , Hartung HP , Calabresi PA Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale . Neurology 2005; 64: 1336-1342.

Niino M. , Bodner C. , Simard ML , et al. Natalizumab effects on immune cell responses in multiple sclerosis . Ann Neurol 2006; 59: 748-754.

Stuve O. , Marra CM , Bar-Or A. , et al. Altered CD4+/ CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63: 1383-1387.

Stuve O. , Bennett JL Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007; 13: 79-95.

Miller DH , Khan OA , Sheremata WA , et al. A controlled trial of natalizumab for relapsing multiple sclerosis . N Engl J Med 2003; 348: 15-23.

Polman CH , O’Connor PW , Havrdova E. , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.

Hamann I. , Zipp F. , Infante-Duarte C. Therapeutic targeting of chemokine signaling in multiple sclerosis. J Neurological Sci 2008; 274: 31-38.

Ubogu EE , Cossoy MB , Ransohoff RM The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006; 27: 48-55.

Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.

10.

Miotto D. , Christodoulopoulos P. , Olivenstein R. , et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol 2001; 107: 664-670.

11.

Singh, U.P. , et al., IFN-γ-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res. , 2003. 23: pp. 591-600).

12.

Kakinuma T. , Nakamura K. , Wakugawa M. , et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis . Clin Exp Immunol 2002; 127: 270-273.

13.

Yamashita U. , Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 2002; 22: 105-114.

14.

Fujisawa T. , Fujisawa R. , Kato Y. , et al. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110: 139-146.

15.

Hijnen D. , De Bruin-Weller M. , Oosting B. , et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113: 334-340.

16.

Khademi M. , Bornsen L. , Rafatnia F. , et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009; 16: 528-536.

17.

McDonald WI , Compston A. , Edan G. , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

18.

Stuve O. , Marra CM , Jerome KR , et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747.

19.

Vrethem M. , Dahle C. , Ekerfelt C. , Forsberg P. , Danielsson O. , Ernerudh J. CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls. Acta Neurol Scand 1998; 97: 215-220.

20.

Jansson A. , Ernerudh J. , Kvarnstrom M. , Ekerfelt C. , Vrethem M. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. Mult Scler 2003; 9: 440-445.

21.

Khademi M. , Wallstrom E. , Andersson M. , Piehl F. , Di Marco R. , Olsson T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000; 103: 202-210.

22.

Jensen J. , Krakauer M. , Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 2005; 29: 24-30.

23.

Duddy ME , Armstrong MA , Crockard AD , Hawkins SA Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis. J Neuroimmunol 1999 ; 101: 98-109.

24.

Franciotta D. , Martino G. , Zardini E. , et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-198.

25.

Man S. , Ubogu EE , Ransohoff RM Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 2007; 17: 243-250.

26.

Szczucinski A. , Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007; 115: 137-146.

27.

Sorensen TL , Tani M. , Jensen J. , et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-815.

28.

Arimilli S. , Ferlin W. , Solvason N. , Deshpande S. , Howard M. , Mocci S. Chemokines in autoimmune diseases. Immunol Rev 2000; 177: 43-51.

29.

Simpson JE , Newcombe J. , Cuzner ML , Woodroofe MN Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26: 133-142.

30.

Subileau EA , Rezaie P. , Davies HA , et al. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis . J Neuropathol Exp Neurol 2009; 68: 227-240.

31.

Flynn G. , Maru S. , Loughlin J. , Romero IA , Male D. Regulation of chemokine receptor expression in human microglia and astrocytes . J Neuroimmunol 2003; 136: 84-93.

32.

Balashov KE , Rottman JB , Weiner HL , Hancock WW CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96: 6873-6878.